DDInter255 DDInter119
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
Busulfan {u} (Compound) binds {v} (Gene) MGST2
Busulfan {u} (Compound) upregulates {v} (Gene) DUSP11
Busulfan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Busulfan {u} (Compound) downregulates {v} (Gene) MRPL19
Busulfan {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Busulfan (Compound) treats hematologic cancer (Disease)
Busulfan (Compound) binds MGST2 (Gene)
Busulfan (Compound) upregulates DUSP11 (Gene)
Busulfan (Compound) is included by Alkylating Activity (Pharmacologic Class)
Busulfan (Compound) downregulates MRPL19 (Gene)
Busulfan (Compound) causes Dermatitis bullous (Side Effect)